Literature DB >> 22225954

Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease.

Qianming Bai1, Xin Zhang, Leyuan Xu, Genta Kakiyama, Douglas Heuman, Arun Sanyal, William M Pandak, Lianhua Yin, Wen Xie, Shunlin Ren.   

Abstract

Cytosolic sulfotransferase (SULT2B1b) catalyzes oxysterol sulfation. 5-Cholesten-3β-25-diol-3-sulfate (25HC3S), one product of this reaction, decreases intracellular lipids in vitro by suppressing liver X receptor/sterol regulatory element binding protein (SREBP)-1c signaling, with regulatory properties opposite to those of its precursor 25-hydroxycholesterol. Upregulation of SULT2B1b may be an effective strategy to treat hyperlipidemia and hepatic steatosis. The objective of the study was to explore the effect and mechanism of oxysterol sulfation by SULT2B1b on lipid metabolism in vivo. C57BL/6 and LDLR(-/-) mice were fed with high-cholesterol diet or high-fat diet for 10 weeks and infected with adenovirus encoding SULT2B1b. SULT2B1b expressions in different tissues were determined by immunohistochemistry and Western blot. Sulfated oxysterols in liver were analyzed by high-pressure liquid chromatography. Serum and hepatic lipid levels were determined by kit reagents and hematoxylin and eosin staining. Gene expressions were determined by real-time reverse transcriptase polymerase chain reaction and Western Blot. Following infection, SULT2B1b was successfully overexpressed in the liver, aorta, and lung tissues, but not in the heart or kidney. SULT2B1b overexpression, combined with administration of 25-hydroxycholesterol, significantly increased the formation of 25HC3S in liver tissue and significantly decreased serum and hepatic lipid levels, including triglycerides, total cholesterol, free cholesterol, and free fatty acids, as compared with controls in both C57BL/6 and LDLR(-/-) mice. Gene expression analysis showed that increases in SULT2B1b expression were accompanied by reduction in key regulators and enzymes involved in lipid metabolism, including liver X receptor α, SREBP-1, SREBP-2, acetyl-CoA carboxylase-1, and fatty acid synthase. These findings support the hypothesis that 25HC3S is an important endogenous regulator of lipid biosynthesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22225954      PMCID: PMC3342481          DOI: 10.1016/j.metabol.2011.11.014

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  38 in total

1.  Biochemical characterization and tissue distribution of human SULT2B1.

Authors:  W J Geese; R B Raftogianis
Journal:  Biochem Biophys Res Commun       Date:  2001-10-19       Impact factor: 3.575

Review 2.  Physiological role of lecithin-cholesterol acyltransferase.

Authors:  J A Glomset
Journal:  Am J Clin Nutr       Date:  1970-08       Impact factor: 7.045

Review 3.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

4.  Key regulatory oxysterols in liver: analysis as delta4-3-ketone derivatives by HPLC and response to physiological perturbations.

Authors:  Z Zhang; D Li; D E Blanchard; S R Lear; S K Erickson; T A Spencer
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

Review 5.  Nonalcoholic steatohepatitis.

Authors:  Elizabeth M Brunt
Journal:  Semin Liver Dis       Date:  2004-02       Impact factor: 6.115

6.  Overexpression of cholesterol transporter StAR increases in vivo rates of bile acid synthesis in the rat and mouse.

Authors:  Shunlin Ren; Phillip B Hylemon; Dalila Marques; Emily Gurley; Patricia Bodhan; Elizabeth Hall; Kaye Redford; Gregorio Gil; William M Pandak
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

7.  Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes.

Authors:  William M Pandak; Shunlin Ren; Dalila Marques; Elizabeth Hall; Kaye Redford; Darrell Mallonee; Patricia Bohdan; Douglas Heuman; Gregorio Gil; Phillip Hylemon
Journal:  J Biol Chem       Date:  2002-10-03       Impact factor: 5.157

8.  Effect of increasing the expression of cholesterol transporters (StAR, MLN64, and SCP-2) on bile acid synthesis.

Authors:  Shunlin Ren; Phillip Hylemon; Dalila Marques; Elizabeth Hall; Kaye Redford; Gregorio Gil; William M Pandak
Journal:  J Lipid Res       Date:  2004-09-01       Impact factor: 5.922

9.  A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly.

Authors:  J D Curb; R D Abbott; B L Rodriguez; K Masaki; R Chen; D S Sharp; A R Tall
Journal:  J Lipid Res       Date:  2004-02-16       Impact factor: 5.922

10.  Conservation of the hydroxysteroid sulfotransferase SULT2B1 gene structure in the mouse: pre- and postnatal expression, kinetic analysis of isoforms, and comparison with prototypical SULT2A1.

Authors:  Chikara Shimizu; Hirotoshi Fuda; Hidekatsu Yanai; Charles A Strott
Journal:  Endocrinology       Date:  2003-04       Impact factor: 4.736

View more
  17 in total

Review 1.  Regulation of the cytosolic sulfotransferases by nuclear receptors.

Authors:  Melissa Runge-Morris; Thomas A Kocarek; Charles N Falany
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

2.  Isoform-specific therapeutic control of sulfonation in humans.

Authors:  Ian Cook; Ting Wang; Thomas S Leyh
Journal:  Biochem Pharmacol       Date:  2018-11-10       Impact factor: 5.858

3.  Transcriptional Regulation of Cytosolic Sulfotransferase 1C2 by Intermediates of the Cholesterol Biosynthetic Pathway in Primary Cultured Rat Hepatocytes.

Authors:  Elizabeth A Rondini; Asmita Pant; Thomas A Kocarek
Journal:  J Pharmacol Exp Ther       Date:  2015-10-01       Impact factor: 4.030

4.  Phytosterols Synergize With Endotoxin to Augment Inflammation in Kupffer Cells but Alone Have Limited Direct Effect on Hepatocytes.

Authors:  Gregory Guthrie; Bryan Tackett; Barbara Stoll; Camilia Martin; Oluyinka Olutoye; Douglas G Burrin
Journal:  JPEN J Parenter Enteral Nutr       Date:  2017-12-11       Impact factor: 4.016

5.  5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

Authors:  Leyuan Xu; Jin Koung Kim; Qianming Bai; Xin Zhang; Genta Kakiyama; Hae-Ki Min; Arun J Sanyal; William M Pandak; Shunlin Ren
Journal:  Mol Pharmacol       Date:  2012-12-20       Impact factor: 4.436

6.  Mechanisms of oxysterol-induced disease: insights from the biliary system.

Authors:  Rahul Kuver
Journal:  Clin Lipidol       Date:  2012-10-01

Review 7.  Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation.

Authors:  Shunlin Ren; Yanxia Ning
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-03       Impact factor: 4.310

8.  Cholesterol metabolite, 5-cholesten-3β-25-diol-3-sulfate, promotes hepatic proliferation in mice.

Authors:  Xin Zhang; Qianming Bai; Genta Kakiyama; Leyuan Xu; Jin Kyung Kim; William M Pandak; Shunlin Ren
Journal:  J Steroid Biochem Mol Biol       Date:  2012-06-23       Impact factor: 4.292

9.  Regulation of Cholesterol Sulfotransferase SULT2B1b by Hepatocyte Nuclear Factor 4α Constitutes a Negative Feedback Control of Hepatic Gluconeogenesis.

Authors:  Yuhan Bi; Xiongjie Shi; Junjie Zhu; Xiudong Guan; Wojciech G Garbacz; Yixian Huang; Li Gao; Jiong Yan; Meishu Xu; Songrong Ren; Shunlin Ren; Yulan Liu; Xiaochao Ma; Song Li; Wen Xie
Journal:  Mol Cell Biol       Date:  2018-03-15       Impact factor: 4.272

10.  Cholesterol sulfate and cholesterol sulfotransferase inhibit gluconeogenesis by targeting hepatocyte nuclear factor 4α.

Authors:  Xiongjie Shi; Qiuqiong Cheng; Leyuan Xu; Jiong Yan; Mengxi Jiang; Jinhan He; Meishu Xu; Maja Stefanovic-Racic; Ian Sipula; Robert Martin O'Doherty; Shunlin Ren; Wen Xie
Journal:  Mol Cell Biol       Date:  2013-11-25       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.